Update on Kaposi sarcoma-associated herpesvirus (KSHV or HHV8) – review

1. BRAY F, FERLAY J, SOERJOMATARAM I, SIEGEL RL, TORRE LA, JEMAL A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394–424.10.3322/caac.2149230207593Search in Google Scholar

2. CHANG Y, CESARMAN E, PESSIN MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994; 266(5192): 1865–9.10.1126/science.79978797997879Search in Google Scholar

3. CALABRO ML, SARID R. Human Herpesvirus 8 and Lymphoproliferative Disorders. Mediterr J Hematol Infect Dis 2018; 10(1): e2018061.10.4084/mjhid.2018.061622357530416693Search in Google Scholar

4. ARVIN A, CAMPIDELLI-FIUME G, MOCARSKI E, MOORE PS, ROIZMAN B, WHITLEY R, YAMANISHI K. Human Herpesviruses: Biology, Therapy and Immunoprophylaxis. Cambridge University Press, Cambridge, 2007: 341–903.10.1017/CBO9780511545313Search in Google Scholar

5. LABO N, WHITBY D. Kaposi’s Sarcoma-Associated Herpesvirus: Epidemiology and Clinical Features of Related Cancer. In: Viruses and Human Cancer. Springer Science+Business Media, New York, 2014: 323–340.10.1007/978-1-4939-0870-7_13Search in Google Scholar

6. DEDICOAT M, NEWTON R. Review of the distribution of Kaposi’s sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi’s sarcoma. Br J Cancer. 2003; 88(1): 1–3.10.1038/sj.bjc.6600745237677112556950Search in Google Scholar

7. ENGELS EA, ATKINSON JO, GRAUBARD BI, MCQUILLAN GM, GAMACHE C, MBISA G,COHN S, WHITBY D, GOEDERT JJ. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis. 2007; 196(2): 199–207.10.1086/51879117570106Search in Google Scholar

8. TEDESCHI R, DILLNER J, PAOLI P. Laboratory Diagnosis of Human Herpesvirus 8 Infection in Humans. Eur J Clin Microbiol Infect Dis. 2002; 21(12): 831–844.10.1007/s10096-002-0836-812525917Search in Google Scholar

9. CESARMAN E, DAMANIA B, KROWN SE, MARTIN J, BOWER M, WHITBY D. Kaposi sarcoma. Nat Rev Dis Primers. 2019; 5(1): 9.10.1038/s41572-019-0060-9668521330705286Search in Google Scholar

10. MESRI EA, CESARMAN E, BOSHOFF C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010; 10(10): 707–719.10.1038/nrc2888472166220865011Search in Google Scholar

11. MARTIN JN, GANEM DE, OSMOND DH et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998; 338(14): 948–954.10.1056/NEJM1998040233814039521982Search in Google Scholar

12. MARCELIN AG, ROQUE-AFONSO AM, HURBOVA M et al. Fatal disseminated Kaposi’s sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transpl. 2004; 10(2): 295–300.10.1002/lt.20058Search in Google Scholar

13. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed: 11 April 2020.Search in Google Scholar

14. MARTIN JN. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and Kaposi sarcoma. Adv Dent Res. 2011; 23: 76–78.10.1177/0022034511399913Search in Google Scholar

15. BARESOVA P, PITHA PM, LUBYOVA B. Distinct roles of Kaposi’s sarcoma-associated herpesvirus-encoded viral interferon regulatory factors in inflammatory response and cancer. J Virol. 2013; 87(17): 9398–9410.10.1128/JVI.03315-12Search in Google Scholar

16. MERCADER M, TADDEO B, PANELLA JR, et al. Induction of KSHV lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am J Pathol 2000; 156(6): 1961–71.10.1016/S0002-9440(10)65069-9Search in Google Scholar

17. CAVALLIN LE, GOLDSCHMIDT-CLERMONT P, MESRI EA. Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi’s sarcoma associated with HIV/AIDS. PLoS Pathog. 2014; 10(7): e1004154.10.1371/journal.ppat.1004154409213125010730Search in Google Scholar

18. WARREN-GASH C, FORBES HJ, WILLIAMSON E, et al. Human herpesvirus infections and dementia or mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2019; 9(1): 4743.10.1038/s41598-019-41218-w642694030894595Search in Google Scholar

19. NAGY S, GYULAI R, KEMENY L, et al. Iatrogenic Kaposi’s sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation 2000; 69:2230.10.1097/00007890-200005270-0005310852635Search in Google Scholar

20. KIMBALL LE, CASPER C, KOELLE DM, et al. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis 2004; 189: 2016.10.1086/38637115143468Search in Google Scholar

21. MULAMA DH, MUTSVUNGUMA LZ, TOTONCHY J, et al. A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits. Vaccine. 2019; 37(30): 4184–4194.10.1016/j.vaccine.2019.04.071687661931201053Search in Google Scholar

22. ARAMĂ V, STREINU CERCEL A. Infecţii cu herpesvirusuri. Editura InfoMedica, Bucureşti, 2002:439–466.Search in Google Scholar

23. ANDREONI M, SARMATI L, NICASTRI E, et al. Primary Human Herpesvirus 8 Infection in Immunocompetent Children. JAMA. 2002; 287(10): 1295–1300.10.1001/jama.287.10.129511886321Search in Google Scholar

24. LUPPI M, BAROZZI P, SCHULZ TF, SETTI G, STASKUS K, TROVATO R, NARNI F, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med. 2000; 343: 1378–85.10.1056/NEJM200011093431905Search in Google Scholar

25. WANG QJ, JENKINS FJ, JACOBSON LP, KINGSLEY LA, DAY RD, ZHANG ZW, et al. Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood. 2001; 97: 2366–2373.10.1182/blood.V97.8.2366Search in Google Scholar

26. REICHART PA, KHONGKHUNTHIAN P, BENDICK C. Oral manifestations in HIV-infected individuals from Thailand and Cambodia. Medical Microbiology and Immunology 2003; 192: 157–60.10.1007/s00430-002-0168-4Search in Google Scholar

27. FATAHZADEH M, SCHWARTZ RA. Oral Kaposi’s sarcoma: a review and update. Int J Dermatol. 2013; 52: 666–672.10.1111/j.1365-4632.2012.05758.xSearch in Google Scholar

28. JELLIFFE DB, COOK J, DAVIES JN. Disseminated glandular Kaposi sarcoma in a Ugandan child. J Pediatr. 1962; 61: 452–5.10.1016/S0022-3476(62)80378-3Search in Google Scholar

29. DENIS D, SETA V, REGNIER-ROSENCHER E, KRAMKIMEL N, CHANAL J, AVRIL MF et al. A fifth subtype of Kaposi’s sarcoma, classic Kaposi’s sarcoma in men who have sex with men: a cohort study in Paris. J. Eur. Acad. Dermatol. Venereol. 2018; 32: 1377–1384.10.1111/jdv.14831Search in Google Scholar

30. ISCOVICH J, BOFFETTA P, WINKELMANN R, BRENNAN P, AZIZI E, et al. Classic Kaposi’s sarcoma in Jews living in Israel, 1961–1989: a population-based incidence study. AIDS. 1998; 12: 2067.10.1097/00002030-199815000-00019Search in Google Scholar

31. MAURER T, PONTE M, LESLIE K. HIV-associated Kaposi’s sarcoma with a high CD4 count and a low viral load. N Engl J Med. 2007; 357: 1352–1353.10.1056/NEJMc070508Search in Google Scholar

32. QUNIBI W, AKHTAR M, SHETH K, GINN HE, AL-FURAYH O, DEVOL EB, TAHER S, et al. Kaposi’s sarcoma: the most common tumor after renal transplantation in Saudi Arabia. Am J Med. 1988; 84: 225–232.10.1016/0002-9343(88)90418-4Search in Google Scholar

33. WANG J, REID H, KLIMAS N, KOSHELEV M. An unusual series of patients with Kaposi sarcoma. JAAD Case Rep. 2019; 5(8): 646–649.10.1016/j.jdcr.2019.05.016667776431388528Search in Google Scholar

34. BIGI R, LANDIS JT, AN H, CARO-VEGAS C, RAAB-TRAUB N, DITTMER DP. Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A. 2018; 115(48): E11379–E11387.10.1073/pnas.1810128115627548830429324Search in Google Scholar

35. BOWNE WB, LEWIS JJ, FILIPPA DA, NIESVIZKY R, BROOKS AD, BURT ME, et al. The management of unicentric and multicentric Castleman’s disease: A report of 16 cases and a review of the literature. Cancer. 1999; 85(3): 706–17.10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7Search in Google Scholar

36. SOULIER J, GROLLET L, OKSENHENDLER E, CACOUB P, CAZALS-HATEM D, BABINET P, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995; 86: 1276–1280.10.1182/blood.V86.4.1276.bloodjournal8641276Search in Google Scholar

37. BOUVARD V, BAAN R, STRAIF K, GROSSE Y, SECRETAN B, GHISSASSI F, et al. A review of human carcinogens – part B: biological agents. Lancet Oncol. 2009; 10(4): 321–2.10.1016/S1470-2045(09)70096-8Search in Google Scholar

38. INCANI A, MARRAS L, SERRELI G, INGIANNI A, POMPEI R, DEIANA M, et al. Human Herpesvirus 8 infection may contribute to oxidative stress in diabetes type 2 patients. BMC Res Notes. 2020; 13: 75.10.1186/s13104-020-4935-3Search in Google Scholar

39. MANNERS O, MURPHY JC, COLEMAN A, HUGHES DJ, WHITEHOUSE A. Contribution of the KSHV and EBV lytic cycles to tumourigenesis. Curr Opin Virol. 2018; 32: 60–70.10.1016/j.coviro.2018.08.014Search in Google Scholar

40. CHEN J, DAI L, GOLDSTEIN A, ZHANG H, TANG W, FORREST C, et al. Identification of new antiviral agents against Kaposi’s sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation. PLoS Pathog. 2019; 15(12): e1008156.10.1371/journal.ppat.1008156Search in Google Scholar

41. STEBBING J, PORTSMOUTH S, GAZZARD B. How does HAART lead to the resolution of Kaposi’s sarcoma? J Antimicrob Chemother. 2003; 51: 1095–1098.10.1093/jac/dkg199Search in Google Scholar

42. LEBBE C, GARBE C, STRATIGOS AJ, GROB JJ, PAGES C. Diagnosis and treatment of Kaposi’s sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer. 2019; 114: 117–27.10.1016/j.ejca.2018.12.036Search in Google Scholar

43. CHAN K, LADE S, PRINCE H, HARRISON S. Update and new approaches in the treatment of Castleman disease. J Blood Med. 2016; 7: 145–158.10.2147/JBM.S60514Search in Google Scholar